Emma E. Furth

Emma E. Furth

Auto-generated profile, based on publicly available information

Emma E. Furth

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2006 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
PPPaige M. Porrett
Paige M. Porrett
HPHeather Peterman
Heather Peterman
MRMark Rosen
Mark Rosen
SSSeema Sonnad
Seema Sonnad
MSMichael Soulen
Michael Soulen
KOKim M. M Olthoff
Kim M. M Olthoff
The potential for disease progression in patients awaiting liver transplantation for hepatocellular carcinoma (HCC) has encouraged many centers to employ pre-transplant radiofrequency ablation or chemoembolization in an attempt to control tumor burden while patients are on the wait list. Despite general acceptance by the transplant community, few objective data demonstrate pre-transplant treatment efficacy or improved post-transplant outcomes in HCC patients listed with Model for End-Stage Liver Disease (MELD) exception points. To evaluate the utility of pre-transplant therapy in the current MELD era, we retrospectively compared 31 treated patients (T) with 33 untreated (U) controls. Study endpoints included patient and disease-free survival, tumor recurrence, explant tumor viability, and the ability of MRI to detect viable tumor after therapy. Both cohorts had similar demographic, radiographic, and pathologic characteristics, although untreated patients waited longer for transplantation [119 (U) vs. 54 (T) days after MELD assignment, (P = .05); range: 1 day to 21 months]. Only 20% of treated tumors demonstrated complete ablation (necrosis) as defined by histologic examination of the entire lesion. Only 55% of lesions with histologic viable tumor were detected by MRI after pre-transplant therapy. After 36 months of follow-up, there was no difference between the treated and untreated groups in overall survival (84 vs. 91%), disease free survival (74% vs. 85%), cancer recurrence (23% vs. 12%), or mortality from cancer recurrence (57% vs. 25%) (P > 0.1). In conclusion, viable tumor frequently persists after pre-transplant locoregional therapy, and neoadjuvant treatment does not appear to improve post-transplant outcomes in the current MELD era. Liver Transpl 12:665–673, 2006. © 2006 AASLD.

11 January 2022 in Radiology
Verified
Journal Article
Closed access
DTDavid J. Tischfield
David J. Tischfield
AGAlexey Gurevich
Alexey Gurevich
OJOmar Johnson
Omar Johnson
IGIsabela Gatmaytan
Isabela Gatmaytan
GNGregory J. Nadolski
Gregory J. Nadolski
TGTerence Gade
Terence Gade
Transarterial embolization–induced alterations in the tumor immune microenvironment are influenced by underlying liver disease, embolic agent type, and vascular location and result in increased pro... Background Transarterial embolization (TAE) is the most common treatment for hepatocellular carcinoma (HCC); however, there remain limited data describing the influence of TAE on the tumor immune m...

21 February 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
KBKatie E. Blise
Katie E. Blise
SSShamilene Sivagnanam
Shamilene Sivagnanam
CBCourtney B. Betts
Courtney B. Betts
KBKonjit Betre
Konjit Betre
NKNell Kirchberger
Nell Kirchberger
KBKatelyn T. Byrne
Katelyn T. Byrne
Tumor molecular data sets are becoming increasingly complex, making it nearly impossible for humans alone to effectively analyze them. Here, we demonstrate the power of using machine learning (ML) to analyze a single-cell, spatial, and highly multiplexed proteomic data set from human pancreatic cancer and reveal underlying biological mechanisms that may contribute to clinical outcomes. We designed a multiplex immunohistochemistry antibody panel to compare T-cell functionality and spatial localization in resected tumors from treatment-naïve patients with localized pancreatic ductal adenocarcinoma (PDAC) with resected tumors from a second cohort of patients treated with neoadjuvant agonistic CD40 (anti-CD40) monoclonal antibody therapy. In total, nearly 2.5 million cells from 306 tissue regions collected from 29 patients across both cohorts were assayed, and over 1,000 tumor microenvironment (TME) features were quantified. We then trained ML models to accurately predict anti-CD40 treatment status and disease-free survival (DFS) following anti-CD40 therapy based on TME features. Through downstream interpretation of the ML models’ predictions, we found anti-CD40 therapy reduced canonical aspects of T-cell exhaustion within the TME, as compared with treatment-naïve TMEs. Using automated clustering approaches, we found improved DFS following anti-CD40 therapy correlated with an increased presence of CD44+CD4+ Th1 cells located specifically within cellular neighborhoods characterized by increased T-cell proliferation, antigen experience, and cytotoxicity in immune aggregates. Overall, our results demonstrate the utility of ML in molecular cancer immunology applications, highlight the impact of anti-CD40 therapy on T cells within the TME, and identify potential candidate biomarkers of DFS for anti-CD40–treated patients with PDAC.

1 May 1996 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
DFDouglas O. Faigel
Douglas O. Faigel
EFEmma E. Furth
Emma E. Furth
MCMarcia Childs
Marcia Childs
JGJames Goin
James Goin
DMDavid C. Metz
David C. Metz

1 November 1995 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
LML. K. Marchant
L. K. Marchant
MLMarc Levine
Marc Levine
EFE. E. Furth
E. E. Furth

12 March 2026 in Science
Verified
Journal Article
Closed access
MTMinh T. Than
Minh T. Than
LDLucie Dequiedt
Lucie Dequiedt
RSRina Sor
Rina Sor
SNShreya Nair
Shreya Nair
NMNune Markosyan
Nune Markosyan
BSBen Z. Stanger
Ben Z. Stanger
Transformation of pancreatic epithelial cells to malignant pancreatic ductal adenocarcinoma (PDAC) typically involves the progression of precancerous pancreatic intraepithelial neoplasia (PanINs) bearing oncogenic KRAS mutations. Here, we tested the impact of PDAC interception using either RAS(ON) multiselective or RAS(ON) G12D-selective pharmacological inhibitors [RAS(ON) inhibitors] in mouse models of PDAC. Treatment of PanIN-bearing mice with RAS(ON) inhibitors prompted regression of premalignant lesions that translated into a delay in tumor onset and an increase in overall survival (OS). Long-term interception in tumor-prone mice resulted in a median OS of more than 1 year compared with less than 5 months in nonintercepted control mice ( P < 0.0001). Comparing the survival benefits of RAS(ON) inhibition for cancer interception versus RAS(ON) inhibition for cancer treatment, we found that interception provided a greater survival benefit to mice. These findings suggest that a pharmacological approach may reduce premalignant burden and increase survival in PDAC.